Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Phase 4

Dimensional Changes of Peri-implant Tissues Following Jumping Gap Grafting Using Erythropoietin Gel Mixed With Xenograft.

NCT07523412 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 4
Started
2026-04-12
Last updated
2026-04-15

Condition(s) studied

Peri-implant Bone and Soft Tissues

Investigational drug(s) / intervention(s)

Erythropoetin gel mixed with xenogenic bone graftXenogenic bone with gelling aget CMC ( carboxymethyl cellulose)

Erythropoetin gel mixed with xenogenic bone graft: Patients with EPO gel mixed with xenogenic bone graft in the jumping gap of immediate implant.

Xenogenic bone with gelling aget CMC ( carboxymethyl cellulose): Patients with xenogenic bone graft and gelling agent in the jumping gap of immediate implant.

Study summary

This study will be conducted to compare the effect of Erythropoietin gel mixed with xenograft versus xenograft alone in grafting the jumping gap around immediate implant.

Eligibility

Sex
ALL
Min age
20 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: 1. Both genders aged from 20 to 50 years. 2. Systemically free patients as evidenced by Burket's oral health history questionnaire. 3. Patients need the extraction of non-restorable maxillary tooth in esthetic zone and the possibility of immediate placement of implants on the same site with Intact labial plate and interproximal bone levels (socket type 1). 4. Gap space of more than 2 mm between the implant and buccal bone. Exclusion Criteria: 1. Smokers. 2. Pregnant or lactating females. 3. Acute infection at the implant site 4. Patients under any medication that affects the healing. 5. Vulnerable group of patients (prisoners, handicapped, and decisional impaired individuals).

Primary outcome measure(s)

  • Radiographic assessment — 0-6 months
    Radiographic assessment of alveolar bone width by CBCT

Trial sites (1)

FacilityCityRegionStatus
Ahmed Cairo Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07523412 on ClinicalTrials.gov ↗ ← All trials in Egypt